The Variants in the 3 ' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma
Nema prikaza
Autori
Dragičević, SandraKosnik, Mitja
Divac Rankov, Aleksandra
Rijavec, Matija
Milosević, Katarina
Korosec, Peter
Kavalar, Maja Skerbinjek
Nikolić, Aleksandra
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Purpose The maintaining of asthma control is difficult due to high variability in response to therapy among patients. Since matrix metalloproteinase 9 (MMP9) is implicated in inflammation and remodeling of asthmatic airways, it could be associated with adequate response to asthma therapy. The aim of this study was to investigate whether variants in 3' end of the MMP9 gene are associated with clinical phenotype and responsiveness to treatment in children with asthma. Methods The study included 127 asthmatic children from Slovenia. Variants in the 3' end of the MMP9 gene were analyzed by direct DNA sequencing and the obtained results were correlated with clinical parameters. Results Two variants were detected, rs13925 and rs20544. For the variant rs20544, statistically significant difference in airway hyperresponsiveness (p = 0.011) and asthma control (p = 0.049) between genotypes was found. Patients with TT genotype had lower airway sensitivity, and after 12 months of treatment showed s...ignificant improvement in Asthma Control Test (ACT) scores compared to CC and CT genotype. For the variant rs13925, the association with lung function was observed. The carriers of A allele showed noticeable improvement of lung function after the first 6 months of treatment in comparison to the carriers of G allele (p = 0.046). Conclusion The main finding of our study is the association of MMP9 genotypes rs20544 TT and rs13925 AA and AG with better asthma control, and indirectly better response to treatment. Based on these results, MMP9 deserves further research as a potential predictive biomarker for asthma.
Ključne reči:
Variant / Matrix metalloproteinase / Genotype / 3 ' UTRIzvor:
Lung, 2018, 196, 3, 297-303Izdavač:
- Springer, New York
Finansiranje / projekti:
- Slovenian Research Agency [P3-0360]
- Kompleksne bolesti kao model sistem za proučavanje modulacije fenotipa-strukturna i funkcionalna analiza molekularnih biomarkera (RS-MESTD-Basic Research (BR or ON)-173008)
DOI: 10.1007/s00408-018-0113-y
ISSN: 0341-2040
PubMed: 29600353
WoS: 000431912300005
Scopus: 2-s2.0-85044502940
Institucija/grupa
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Dragičević, Sandra AU - Kosnik, Mitja AU - Divac Rankov, Aleksandra AU - Rijavec, Matija AU - Milosević, Katarina AU - Korosec, Peter AU - Kavalar, Maja Skerbinjek AU - Nikolić, Aleksandra PY - 2018 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1180 AB - Purpose The maintaining of asthma control is difficult due to high variability in response to therapy among patients. Since matrix metalloproteinase 9 (MMP9) is implicated in inflammation and remodeling of asthmatic airways, it could be associated with adequate response to asthma therapy. The aim of this study was to investigate whether variants in 3' end of the MMP9 gene are associated with clinical phenotype and responsiveness to treatment in children with asthma. Methods The study included 127 asthmatic children from Slovenia. Variants in the 3' end of the MMP9 gene were analyzed by direct DNA sequencing and the obtained results were correlated with clinical parameters. Results Two variants were detected, rs13925 and rs20544. For the variant rs20544, statistically significant difference in airway hyperresponsiveness (p = 0.011) and asthma control (p = 0.049) between genotypes was found. Patients with TT genotype had lower airway sensitivity, and after 12 months of treatment showed significant improvement in Asthma Control Test (ACT) scores compared to CC and CT genotype. For the variant rs13925, the association with lung function was observed. The carriers of A allele showed noticeable improvement of lung function after the first 6 months of treatment in comparison to the carriers of G allele (p = 0.046). Conclusion The main finding of our study is the association of MMP9 genotypes rs20544 TT and rs13925 AA and AG with better asthma control, and indirectly better response to treatment. Based on these results, MMP9 deserves further research as a potential predictive biomarker for asthma. PB - Springer, New York T2 - Lung T1 - The Variants in the 3 ' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma EP - 303 IS - 3 SP - 297 VL - 196 DO - 10.1007/s00408-018-0113-y ER -
@article{ author = "Dragičević, Sandra and Kosnik, Mitja and Divac Rankov, Aleksandra and Rijavec, Matija and Milosević, Katarina and Korosec, Peter and Kavalar, Maja Skerbinjek and Nikolić, Aleksandra", year = "2018", abstract = "Purpose The maintaining of asthma control is difficult due to high variability in response to therapy among patients. Since matrix metalloproteinase 9 (MMP9) is implicated in inflammation and remodeling of asthmatic airways, it could be associated with adequate response to asthma therapy. The aim of this study was to investigate whether variants in 3' end of the MMP9 gene are associated with clinical phenotype and responsiveness to treatment in children with asthma. Methods The study included 127 asthmatic children from Slovenia. Variants in the 3' end of the MMP9 gene were analyzed by direct DNA sequencing and the obtained results were correlated with clinical parameters. Results Two variants were detected, rs13925 and rs20544. For the variant rs20544, statistically significant difference in airway hyperresponsiveness (p = 0.011) and asthma control (p = 0.049) between genotypes was found. Patients with TT genotype had lower airway sensitivity, and after 12 months of treatment showed significant improvement in Asthma Control Test (ACT) scores compared to CC and CT genotype. For the variant rs13925, the association with lung function was observed. The carriers of A allele showed noticeable improvement of lung function after the first 6 months of treatment in comparison to the carriers of G allele (p = 0.046). Conclusion The main finding of our study is the association of MMP9 genotypes rs20544 TT and rs13925 AA and AG with better asthma control, and indirectly better response to treatment. Based on these results, MMP9 deserves further research as a potential predictive biomarker for asthma.", publisher = "Springer, New York", journal = "Lung", title = "The Variants in the 3 ' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma", pages = "303-297", number = "3", volume = "196", doi = "10.1007/s00408-018-0113-y" }
Dragičević, S., Kosnik, M., Divac Rankov, A., Rijavec, M., Milosević, K., Korosec, P., Kavalar, M. S.,& Nikolić, A.. (2018). The Variants in the 3 ' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma. in Lung Springer, New York., 196(3), 297-303. https://doi.org/10.1007/s00408-018-0113-y
Dragičević S, Kosnik M, Divac Rankov A, Rijavec M, Milosević K, Korosec P, Kavalar MS, Nikolić A. The Variants in the 3 ' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma. in Lung. 2018;196(3):297-303. doi:10.1007/s00408-018-0113-y .
Dragičević, Sandra, Kosnik, Mitja, Divac Rankov, Aleksandra, Rijavec, Matija, Milosević, Katarina, Korosec, Peter, Kavalar, Maja Skerbinjek, Nikolić, Aleksandra, "The Variants in the 3 ' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma" in Lung, 196, no. 3 (2018):297-303, https://doi.org/10.1007/s00408-018-0113-y . .